Phase IIa study of glatiramer acetate (MyeloXen) for treatment of multiple sclerosis in Russia
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2016
Price : $35 *
At a glance
- Drugs Multiple sclerosis vaccine (Primary)
- Indications Multiple sclerosis
- Focus First in man; Proof of concept; Therapeutic Use
- 01 Apr 2016 Results published in a PJSC Pharmsynthez media release.
- 01 Apr 2016 Status changed from active, no longer recruiting to completed, according to a PJSC Pharmsynthez media release.
- 21 Nov 2014 Dosing of patients completed, according to a Xenetic Biosciences media release.